Cargando…

Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes

Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes—specifically psychosis, agitation, or a combination. A c...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Christoph, John, Christeena, Perera, Gayan, Aarsland, Dag, Ballard, Clive, Stewart, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847435/
https://www.ncbi.nlm.nih.gov/pubmed/32415541
http://dx.doi.org/10.1007/s10654-020-00643-2
_version_ 1783644932270981120
author Mueller, Christoph
John, Christeena
Perera, Gayan
Aarsland, Dag
Ballard, Clive
Stewart, Robert
author_facet Mueller, Christoph
John, Christeena
Perera, Gayan
Aarsland, Dag
Ballard, Clive
Stewart, Robert
author_sort Mueller, Christoph
collection PubMed
description Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes—specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia diagnosis were determined according to the Health of the Nation Outcome Scales’ mental and behavioural problem scores and the sample was divided into four groups: ‘agitation and psychosis’, ‘agitation, but no psychosis’, ‘psychosis, but no agitation’, and ‘neither psychosis nor agitation’. Antipsychotic prescription in a one-year window around first dementia diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, functioning, as well as physical and mental health. Only in the group ‘psychosis, but no agitation’ (n = 579), 30% of whom were prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09–4.25). An increased antipsychotic-related all-cause (adjusted HR 1.14; 95% CI 1.04–1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01–1.63) was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting with psychosis without agitation, indicating the need for novel interventions for this group. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10654-020-00643-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7847435
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-78474352021-02-08 Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes Mueller, Christoph John, Christeena Perera, Gayan Aarsland, Dag Ballard, Clive Stewart, Robert Eur J Epidemiol Psychiatric Epidemiology Antipsychotic treatments are associated with safety concerns in people with dementia. The authors aimed to investigate whether risk of adverse outcomes related to antipsychotic prescribing differed according to major neuropsychiatric syndromes—specifically psychosis, agitation, or a combination. A cohort of 10,106 patients with a diagnosis of dementia was assembled from a large dementia care database in South East London. Neuropsychiatric symptoms closest to first dementia diagnosis were determined according to the Health of the Nation Outcome Scales’ mental and behavioural problem scores and the sample was divided into four groups: ‘agitation and psychosis’, ‘agitation, but no psychosis’, ‘psychosis, but no agitation’, and ‘neither psychosis nor agitation’. Antipsychotic prescription in a one-year window around first dementia diagnosis was ascertained as exposure variable through natural language processing from free text. Cox regression models were used to analyse associations of antipsychotic prescription with all-cause and stroke-specific mortality, emergency hospitalisation and hospitalised stroke adjusting for sixteen potential confounders including demographics, cognition, functioning, as well as physical and mental health. Only in the group ‘psychosis, but no agitation’ (n = 579), 30% of whom were prescribed an antipsychotic, a significant antipsychotic-associated increased risk of hospitalised stroke was present after adjustment (adjusted hazard ratio (HR) 2.16; 95% confidence interval (CI) 1.09–4.25). An increased antipsychotic-related all-cause (adjusted HR 1.14; 95% CI 1.04–1.24) and stroke-specific mortality risk (adjusted HR 1.28; 95% CI 1.01–1.63) was detected in the whole sample, but no interaction between the strata and antipsychotic-related mortality. In conclusion, the adverse effects of antipsychotics in dementia are complex. Stroke risk may be highest when used in patients presenting with psychosis without agitation, indicating the need for novel interventions for this group. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10654-020-00643-2) contains supplementary material, which is available to authorized users. Springer Netherlands 2020-05-15 2021 /pmc/articles/PMC7847435/ /pubmed/32415541 http://dx.doi.org/10.1007/s10654-020-00643-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Psychiatric Epidemiology
Mueller, Christoph
John, Christeena
Perera, Gayan
Aarsland, Dag
Ballard, Clive
Stewart, Robert
Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
title Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
title_full Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
title_fullStr Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
title_full_unstemmed Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
title_short Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
title_sort antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes
topic Psychiatric Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847435/
https://www.ncbi.nlm.nih.gov/pubmed/32415541
http://dx.doi.org/10.1007/s10654-020-00643-2
work_keys_str_mv AT muellerchristoph antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes
AT johnchristeena antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes
AT pereragayan antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes
AT aarslanddag antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes
AT ballardclive antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes
AT stewartrobert antipsychoticuseindementiatherelationshipbetweenneuropsychiatricsymptomprofilesandadverseoutcomes